Alpa Laboratories Limited (532878) fair value: what the stock is really worth
We calculate from audited financials what Alpa Laboratories Limited is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Alpa Laboratories Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range ₹46.25 – ₹139.10 · fair‑value band ₹24.82 – ₹45.00 · the ₹61.85 price screens above the ₹34.03 fair value. Dashed = 300-day average. As of Sep 13, 2026.
Alpa Laboratories Limited engages in manufacturing, marketing, and selling pharmaceutical finished dosage forms in India.
Show more
Alpa Laboratories Limited engages in manufacturing, marketing, and selling pharmaceutical finished dosage forms in India. It offers ethical, generic, and over the counter products in various finished dosage forms, including liquid injections, dry powder injections, tablets, capsules, eye and ear drops, ointments, creams, and gels for human use; and boluses, injections, and intra-mammary infusions for veterinary use. The company provides its products in various categories, such as anti-infectives comprising antibacterial, antibiotics, antifungals, anti protozoans, and antivirals; analgesics; anti-inflammatory drugs; cough and cold drugs; cardiovascular drugs; anti-diabetics; nutritional supplements; psychotropic drugs; and skin care preparations, as well as ear and eye care preparations. Alpa Laboratories Limited sells its products through distributors, as well as retail chemists, retail pharmacy stores, and hospitals. The company also exports its products to various countries in South and Central America, Africa, and Asia, including CIS countries comprising Russia, Ukraine, Kazakhstan, etc. Alpa Laboratories Limited was incorporated in 1988 and is based in Indore, India.
Stock analysis
Alpa Laboratories Limited (532878) currently trades at ₹61.85, while our model-based Fair Value estimate is ₹34.03, implying the stock looks roughly 81.8% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹148.84 per share, and 11 of the 24 models we run sit above the ₹61.85 price.
Bear case: the Economic Profit group reads lowest at ₹7.74, and 13 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹24.82 (bear) to ₹45.00 (bull), the price of ₹61.85 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Alpa Laboratories Limited reported revenue of ₹1.1B in FY2025 versus ₹976M in FY2021, a compound +3.6%/yr. Reported net income was ₹195M in FY2025, compounding +28.1%/yr from FY2021.
Key figures
Market cap ₹1.3B (≈ $13.7M) · P/E ratio 20.2 · P/S ratio 3.50 · EPS (TTM) ₹1.85 · Net margin 17.3% · Return on assets (EBIT) 3.8% · Operating margin 1.4% · Revenue (TTM) ₹821M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 39% below its 52-week high and 34% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −17% fair-value upside, at −45%, 532878 screens richer than that median.
Fair Value models
Bear ₹24.82Fair Value ₹34.03Bull ₹45.00
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (₹1.85 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.56/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+3.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.5%
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+60.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+60.1%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 2%
Compare Alpa Laboratories Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Other · 128 stocks
Beats the industry median on 5/11 measures
A mixed picture versus its industry peers.
Valuation
Quality Score49 · Below median
Fair Value upside+19% · Above median
Profitability
Return on assets0% · Above median
Net margin (TTM)5% · Above median
Operating margin (TTM)1% · Above median
Growth and dividend
Revenue growth−19% · Bottom 25%
Dividend yield (TTM)0.0% · Bottom 25%
Valuation Multiplesvs Other median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Alpa Laboratories Limited (532878) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of ₹34.03 versus a price of ₹61.85, about −45% upside (overvalued).
What is the fair value of 532878?
Our model-based fair value for Alpa Laboratories Limited is ₹34.03 (as of Sep 13, 2026), built from audited fundamentals. The current price: ₹61.85.
What is the quality score of 532878?
Alpa Laboratories Limited has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Alpa Laboratories Limited (532878)?
Our model-based price target is the fair value of ₹34.03 (as of Sep 13, 2026) from 24 valuation models. Cautious scenario ₹24.82, optimistic scenario ₹45.00. It is a calculation from audited fundamentals, not an analyst target.
What is the Alpa Laboratories Limited stock forecast for 2026?
Our models put fair value at ₹34.03, about −45% upside versus a price of ₹61.85 (overvalued). Cautious scenario ₹24.82, optimistic scenario ₹45.00. The calculation is refreshed regularly with new filings.
What is the revenue of Alpa Laboratories Limited (532878)?
Alpa Laboratories Limited reported trailing-twelve-month revenue of about ₹821M (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of Alpa Laboratories Limited (532878)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Alpa Laboratories Limited it is ₹34.03 per share (as of Sep 13, 2026), against a price of ₹61.85. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Alpa Laboratories Limited stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 532878 trades above its calculated fair value: price ₹61.85, fair value ₹34.03, a gap of about −45% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 532878?
No. The price is what the market pays today (₹61.85); the fair value is what the company's own numbers justify (₹34.03). For Alpa Laboratories Limited the two are ₹27.82 per share apart. That gap is exactly why we show both numbers side by side.
How much is Alpa Laboratories Limited worth?
The market values Alpa Laboratories Limited at about ₹1.3B (market capitalisation, as of Sep 13, 2026). Per share that is ₹61.85; our models calculate a fair value of ₹34.03 per share.
What do the bullish and bearish scenarios say about 532878?
Our models span a range for Alpa Laboratories Limited: cautious scenario ₹24.82, base ₹34.03, optimistic ₹45.00 per share (as of Sep 13, 2026, price ₹61.85). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 532878?
Alpa Laboratories Limited trades at a price-to-earnings ratio of 20.2 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹34.03 is built from several models across several years. Other multiples: P/B 0.5, P/S 1.1, EV/EBITDA 18.7.
How far is 532878 from its 52-week high?
Alpa Laboratories Limited trades at ₹61.85, about 39% below its 52-week high of ₹101.00 and 34% above the low of ₹46.00 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of ₹34.03 is for.
Which stocks are comparable to Alpa Laboratories Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Alpa Laboratories Limited stock attractive at the current price?
The data as of Sep 13, 2026: price ₹61.85, calculated fair value ₹34.03 (−45%), Quality Score 50/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 532878 calculated?
We run Alpa Laboratories Limited through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹34.03, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Alpa Laboratories Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Alpa Laboratories Limited right now?
The price sits above even our optimistic bull case (₹45.00). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹24.82 to ₹45.00) leaves room in how you read the outcome.
Key figures of Alpa Laboratories Limited
How large is the market capitalisation of Alpa Laboratories Limited (532878)?
The market capitalisation of Alpa Laboratories Limited is ₹1.3B (≈ $13.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Alpa Laboratories Limited (532878)?
The price-to-sales ratio of Alpa Laboratories Limited is 3.50 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Alpa Laboratories Limited (532878)?
Earnings per share at Alpa Laboratories Limited are ₹1.85 (price ÷ EPS = P/E 20.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Alpa Laboratories Limited (532878)?
The net margin of Alpa Laboratories Limited is 17.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Alpa Laboratories Limited (532878)?
On an EBIT basis the return on assets of Alpa Laboratories Limited is 3.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Alpa Laboratories Limited (532878)?
The operating margin of Alpa Laboratories Limited is 1.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Alpa Laboratories Limited (532878)?
Revenue at Alpa Laboratories Limited is growing −19.2% versus a year earlier (3y avg +0.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Alpa Laboratories Limited (532878)?
Earnings per share at Alpa Laboratories Limited are growing +164% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Alpa Laboratories Limited in the live analysis
One click puts Alpa Laboratories Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
